首页> 外文期刊>Annals of surgical oncology >Low-dose preoperative chemoradiation therapy compared with surgery alone with or without postoperative radiotherapy in patients with head and neck carcinoma.
【24h】

Low-dose preoperative chemoradiation therapy compared with surgery alone with or without postoperative radiotherapy in patients with head and neck carcinoma.

机译:头颈癌患者低剂量术前放化疗与单纯手术联合或不联合术后放疗的比较。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Several multimodal strategies have been developed to treat patients with squamous cell carcinoma of the oral cavity (OSCC), and many have shown survival benefits. The theoretical advantages of preoperative chemoradiotherapy are downstaging of the primary tumor, an increased resectability rate, and the elimination of micrometastases. We aimed to assess whether a short low-dose preoperative radiotherapy regimen with concurrent low-dose chemotherapy with cisplatin improves outcomes for patients with OSCC undergoing surgical treatment with curative intent. METHODS: A total of 407 patients received preoperative low-dose radiotherapy of 20 Gy given in 10 fractions with concurrent low-dose chemotherapy with cisplatin (12.5 mg/m(2)) as part of a pre-existing protocol. This was compared with 519 patients receiving surgery alone. Endpoints were overall survival, tumor response, and toxic effects. Analysis was controlled for tumor-related and demographic factors. RESULTS: After controlling for age, tumor stage, nodal stage, tumor grade, recurrence, and resection margin status, which were independent and dependent predictors of survival, preoperative radiotherapy was associated with improved survival [0.79; P = 0.002; 95% confidence interval (95% CI), 0.66-0.96], in patients receiving only preoperative radiation therapy or in combination with/without postoperative radiotherapy (1.31; P = 0.041; 95% CI, 1.01-1.70 with postoperative radiotherapy; 1.40; P = 0.039; 95% CI, 1.01-1.85 without postoperative radiotherapy). CONCLUSIONS: Low-dose preoperative radiotherapy combined with low-dose chemotherapy with cisplatin significantly improves overall survival for patients with resectable OSCC compared with surgery alone.
机译:背景:已经开发出了多种治疗口腔鳞状细胞癌(OSCC)患者的多式联运策略,并且许多方法已显示出生存益处。术前放化疗的理论优势是降低原发肿瘤的分期,增加可切除率和消除微转移。我们的目的是评估短期的低剂量术前放疗方案与顺铂同时进行的低剂量化疗是否可以改善以手术方式治疗的OSCC患者的预后。方法:共有407例患者接受了术前低剂量放疗20 Gy,分10步进行,同时作为既往治疗方案的一部分,同时进行顺铂(12.5 mg / m(2))低剂量化疗。将其与仅接受手术的519例患者进行了比较。终点是总生存期,肿瘤反应和毒性作用。分析控制与肿瘤相关和人口统计学因素。结果:在控制了年龄,肿瘤分期,淋巴结分期,肿瘤分级,复发和切除切缘状态后,这些是独立且独立的生存预测指标,术前放疗与生存率提高相关[0.79; P = 0.002;仅接受术前放疗或联合/不联合术后放疗的患者的置信区间(95%CI)为[0.66-0.96](1.31; P = 0.041; 95%CI:术后放疗的1.01-1.70; 1.40; 1.00 P = 0.039; 95%CI,未经术后放疗的1.01-1.85)。结论:与单独手术相比,术前低剂量放疗联合顺铂低剂量化疗可显着提高可切除OSCC患者的总体生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号